Premium
Variation in breast cancer care quality in N ew Y ork and C alifornia based on race/ethnicity and M edicaid enrollment
Author(s) -
Hassett Michael J.,
Schymura Maria J.,
Chen Kun,
Boscoe Francis P.,
Gesten Foster C.,
Schrag Deborah
Publication year - 2016
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.29777
Subject(s) - medicine , medicaid , ethnic group , breast cancer , pacific islanders , concordance , socioeconomic status , demography , gerontology , cancer , health equity , family medicine , health care , public health , environmental health , population , nursing , sociology , anthropology , economics , economic growth
BACKGROUND Racial/ethnic and socioeconomic disparities persist in part because our current understanding of the care provided to minority and disadvantaged populations is limited. The authors evaluated the quality of breast cancer care in 2 large states to understand the disparities experienced by African Americans, Hispanics, Asian/Pacific Islanders (APIs), and Medicaid enrollees and to prioritize remediation strategies. METHODS Statewide cancer registry data for 80,436 women in New York and 121,233 women in California who were diagnosed during 2004 to 2009 with stage 0 through III breast cancer were used to assess underuse and overuse of surgery, radiation, chemotherapy, and hormone therapy based on 34 quality measures. Concordance values were compared across racial/ethnic and Medicaid‐enrollment groups. Multivariable models were used to quantify disparities across groups for each treatment in each state. RESULTS Overall concordance was 76% for underuse measures and 87% for overuse measures. The proportions of patients who received care concordant with all relevant measures were 35% in New York and 33% in California. Compared with whites, African Americans were less likely to receive recommended surgery, radiation, and hormone therapy; Hispanics and APIs were usually more likely to receive recommended chemotherapy. Across states, the same racial/ethnic groups did not always experience the same disparities. Medicaid enrollment was associated with decreased likelihood of receiving all recommended treatments, except chemotherapy, in both states. Overuse was evident for hormone therapy and axillary surgery but was not associated with race/ethnicity or Medicaid enrollment. CONCLUSIONS Patient‐level measures of quality identify substantial problems with care quality and meaningful disparities. Remediating these problems will require prioritizing low‐performing measures and targeting high‐risk populations, possibly in different ways for different regions. Cancer 2016;122:420–431. © 2015 American Cancer Society .